MarketPulse
C

$CNTA

11 articles found
8 positive
0 negative
3 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Nxera Pharma Posts Strong Q1 2026 as Spinoff Centessa Fetches $7.8B Lilly Deal

Nxera Pharma reported JPY 11.3B Q1 revenue driven by R&D milestones. Spinoff Centessa agreed to $7.8B acquisition by Eli Lilly.
ABBVLLYCNTANBIXrevenue growthdrug discovery
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Beyond Weight Loss: Eli Lilly's Diversified Pipeline Offers More Growth Than Rivals

Eli Lilly's oncology and immunology portfolios rival its blockbuster weight-loss drugs, positioning the company better than Novo Nordisk for long-term growth.
LLYNVOCNTAgene therapyweight loss drugs
The Motley FoolThe Motley Fool··Eric Volkman

Eli Lilly's $6.3B Centessa Deal Signals Aggressive Push Into Neuroscience

Eli Lilly acquires Centessa Pharmaceuticals for $6.3B, gaining neuroscience assets. Stock rises on strong financial footing from weight-loss drug success.
LLYCNTAbiotechclinical trials
The Motley FoolThe Motley Fool··Motley Fool Staff

M&A Surge Reshapes Food and Pharma: $78B in Mega-Deals Signals Strategic Consolidation

Sysco, McCormick, and Eli Lilly announce $78B in major acquisitions spanning foodservice, consumer staples, and pharma, signaling significant industry consolidation.
LLYSYYCNTAWHRKDP+8dividend stocksM&A
BenzingaBenzinga··Caroline Ryan

Wave of Mega Deals Reshape Food, Pharma Sectors Amid QVC Bankruptcy Concerns

McCormick merges with Unilever Foods for $29.1B while Sysco acquires Jetro for $29B; QVC explores bankruptcy amid retail distress.
AMZNLLYQXOQXOpBSYY+10Syscofood distribution
Investing.comInvesting.com··Jeffrey Neal Johnson

Lilly Bets $10B on AI and Neuroscience to Diversify Beyond GLP-1 Boom

Eli Lilly commits $10B to AI drug discovery partnership and sleep disorders acquisition, diversifying beyond its GLP-1 franchise.
LLYCNTArevenue diversificationartificial intelligence
BenzingaBenzinga··Not Specified

Eli Lilly's Centessa Acquisition Validates Nxera's Drug Discovery Platform

Eli Lilly acquires Centessa Pharmaceuticals, which developed sleep-disorder treatments with Nxera Pharma. Nxera retains royalties, milestones, and equity stake.
LLYCNTAacquisitiondrug discovery
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Eli Lilly Acquires Centessa Pharmaceuticals in Sleep-Wake Drug Push

Eli Lilly acquires Centessa Pharmaceuticals, developer of OX2R agonists for sleep disorders co-created with Nxera Pharma, which retains milestone payments and royalties.
LLYCNTAacquisitiondrug discovery
BenzingaBenzinga··Vandana Singh

Eli Lilly to Acquire Centessa for $6.3B, Bolstering Sleep Medicine Push

Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B upfront plus $1.5B in contingent payments, gaining sleep disorder pipeline including cleminorexton candidate.
LLYCNTAacquisitionneuroscience
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Pharmaceuticals Outpaces Centessa With Established Revenue and Advanced Pipeline

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.
VRTXCNTAbiotechclinical trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Exits Majority Centessa Stake as Stock Rallies 53%

Commodore Capital exits majority Centessa stake, selling 1.85M shares for $46.86M amid 53% stock rally and company's strategic leadership changes.
CNTAbiotechclinical-stage